endogene.bio was selected as one of the winners of the 2024 i-Lab competition, a national innovation program organized by Bpifrance as part of the France 2030 initiative. The i-Lab competition is dedicated to identifying and supporting some of France's most innovative startups, providing winners with both substantial funding and tailored support. It plays a key role in fostering technological innovation across industries and helping early-stage companies bring breakthrough ideas to market.
For endogene.bio, this recognition highlights the company's work in biomarker discovery and women's health. By developing new tools to improve health outcomes for women and addressing conditions that have historically been under-researched, endogene.bio is helping advance the future of uterine health. The i-Lab award provides both the resources and validation needed to accelerate research efforts and further the development of new diagnostic and therapeutic solutions.
About endogene.bio
endogene.bio generates high-resolution biological data from menstrual blood, unlocking a previously inaccessible layer of human uterine biology. Our platform enables disease understanding, patient stratification, and therapeutic discovery across uterine health.
